← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Childrens Hospital Medical Center
$40,901,086
Total funding
58
Grants
Funding over time
peak $7.4M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$39,979,015 · 56
NASA$922,071 · 1
NIH$0 · 1
By mechanism
—$40,901,086 · 57
N01$0 · 1
Investigators at Childrens Hospital Medical Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
REGULATING TOGETHER: RANDOMIZED CONTROLLED TRIAL EXAMINING PREDICTORS, FACILITATORS, AND BARRIERS TO TREATMENT SUCCESS IN EMOTION DYSREGULATION AND ASD$2,655,472
· FY2022 · Department of the Army
MITOCHONDRIAL ALR PROTEIN DEFICIENCY DRIVES PROGRESSIVE ALCOHOL LIVER DISEASE$1,803,889
· FY2020 · Defense Health Agency
THERAPEUTIC BENEFIT OF HSP90 INHIBITION IN PULMONARY FIBROSIS$1,757,427
· FY2017 · Department of the Army
INFLAMMATORY VIGOR IN HETEROGENEITY OF TYPE 2 DIABETES (T2D) DEVELOPMENT, SEVERITY, AND RESOLUTION$1,748,664
· FY2020 · Defense Health Agency
IL-9-PRODUCING MAST CELL PRECURSORS AND FOOD ALLERGY$1,638,000
· FY2015 · Department of Defense
NOVEL RAC PATHWAY INHIBITORS FOR THE TREATMENT OF METASTATIC RAS/MAPK ACTIVATED LEUKEMIA$1,564,751
· FY2025 · Defense Health Agency
FAMILY-CENTERED E-HEALTH INTERVENTION TO PROMOTE PATIENT AND CAREGIVER WELL-BEING IN ADOLESCENT AND EMERGING ADULT PEDIATRIC BRAIN TUMOR SURVIVORS$1,354,428
· FY2024 · Defense Health Agency
SHIGELLA DOSE FINDING STUDY$1,340,373
· FY2016 · Department of the Army
MECHANISMSOF NONALCOHOLIC STEATOHEPATITIS$1,329,135
· FY2015 · Department of the Army
ANTIOXIDANT THERAPY WITH N-ACETYLCYSTEINE FOR MOTOR BEHAVIOR AND LEARNING IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1$1,268,303
· FY2020 · Defense Health Agency
DELAYED OUTCOME MECHANISMS IN CHRONIC TRAUMATIC OPTIC NEUROPATHY$1,189,549
· FY2022 · Defense Health Agency
REGULATING TOGETHER IN TUBEROUS SCLEROSIS COMPLEX. A PILOT FEASIBILITY STUDY IN CHILDREN AND ADOLESCENTS WITH TSC ASSOCIATED NEUROPSYCHIATRIC DISORDER$1,188,902
· FY2025 · Defense Health Agency
GENOME-WIDE ASSOCIATION STUDY IN AFRICAN-AMERICANS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$1,146,369
· FY2010 · Department of Defense
IDENTIFICATION OF MOLECULAR AND CELLULAR CONTRIBUTORS TO NEUROFIBROMA FORMATION AND GROWTH$1,022,508
· FY2012 · Department of Defense
FOLLICULAR T-CELL TARGETING IN THERAPY OF LUPUS$1,000,000
· FY2024 · Defense Health Agency
THE SUCCESSFUL DIASPORA OF HUMANS INTO DEEP SPACE REQUIRES AN UNDERSTANDING OF THE RISK OF DEEP SPACE RADIATION EXPOSURE ON SHORT AND LONG TERM HEALT$922,071
· FY2014 · National Aeronautics and Space Administration
SCHWANN CELL INTERACTIONS WITH THE NEUROFIBROMA MICROENVIRONMENT$897,001
· FY2017 · Department of the Army
W81XWH2010377/MERLIN-ASPP2 TUMOR SUPPRESSOR INTERACTIONS IN MECHANOSENSORY SIGNAL TRANSDUCTION FROM SCHWANN CELL JUNCTIONS IN NEUROFIBROMATOSIS TYPE 2. NEW AWARD.$834,750
· FY2020 · Defense Health Agency
IS THERE A POINT OF CONVERGENCE BETWEEN CONGENITAL HEART DISEASE AND AUTISM?$795,000
· FY2022 · Department of the Army
SURVIVING AND THRIVING IN THE REAL WORLD: A DAILY LIVING SKILLS INTERVENTION FOR HIGH SCHOOLERS WITH AUTISM SPECTRUM DISORDER$794,997
· FY2018 · Defense Health Agency